Orthopedics company Cerapedics is expanding its Denver headquarters to support the growth of its products, which include the FDA approved i-Factor bone graft for cervical spinal fusions and its next generation of products for lumbar spinal fusions.
I-Factor is just one of two FDA approved Class III drug-device bone grafts with a spinal indication, according to a July 19 press release.
By expanding its facility, Cerapedics is adding over 50 percent more space for manufacturing, research and development. It has hired more than 100 employees in the state in the last five years and plans to add another 60 by the end of 2024.